Table 2

Summary of studies evaluating eHealth as part of the medical management in PAH

Author/countryType of study/level of evidence (CEBM)/type (and year) of publicationStudy populationInterventionResultsSignificance level
Benza et al
  1. Case-series studies/level 4/CP (2012, 2015 and 2016)

  2. Retrospective cohort study/level 2b/JP (2015)

11 patients with advanced PAH, 6 of them with a recent hospitalisation for RHF
CHAMPION study population
Haemodynamically guided management of patients through Cardiomems
  1. CardioMEMS monitoring was safe at rest and during a 6MWT in PAH, and reduced hospitalisation rates in HF patients with PH

  2. CardioMEMS associated to a greater PAP reduction through medication changes in the ambulatory setting. Among patients with PH, there was a reduction in the composite endpoint of death and HF hospitalisation with ongoing knowledge of haemodynamics, but no difference in survival

1. 36% reduction in HF-related hospitalisation rates
(0.60 vs 0.94, HR 0.64, 95% CI 0.51 to 0.81, p=0.0002)
2. Composite endpoint: HR 0.74, 95% CI 0.55 to 0.99, p=0.04
Survival: HR 0.78, 95% CI 0.50 to 1.22, p=0.28
Raina et al
Retrospective cohort study/level 2b/CP (2014)314 WHO Group 2 patients with PH from the CHAMPION studyRetrospective analysis of Cardiomems patientsCardiomems associated with hospitalisation reductions in Group 2 patients with PAHHR 0.64, 95% CI 0.51 to 0.81
  • CEBM: Centre for Evidence-Based Medicine, Oxford University( CHAMPION study population: 550 patients with heart failure with Cardiomems; 314 of them with WHO Group 2 PAH.

  • CEBM, Centre for Evidence-Based Medicine; CP, conference paper; JP, journal paper; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PH, pulmonary hypertension; RHF, right heart failure.